Larvol Delta - CERo-Therapeutics-Inc-Receives-FDA-Clearance-of-Investigational-New-Drug-Application-to-Initiate-Phase-1-Clinical-Trial-of-Its-Lead-Compound-CER1236-in-Acute-Myelogenous-Leukemia

CER-1236 - CERo Therap

https://www.globenewswire.com/news-release/2024/11/15/2982017/0/en/CERo-Therapeutics-Inc-Receives-FDA-Clearance-of-Investigational-New-Drug-Application-to-Initiate-Phase-1-Clinical-Trial-of-Its-Lead-Compound-CER-1236-in-Acute-Myelogenous-Leukemia.html

Nov 15, 2024

SHARE THIS

Print
Email
More sharing

Reddit

StumbleUpon

Delicious

Prev Next